Singapur - angličtina - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - clottable protein (human fibrinogen); human thrombin - solution - 50-90 mg/ml - clottable protein (human fibrinogen) 50-90 mg/ml; human thrombin 800-1200 iu/ml

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd - human thrombin, quantity: 800 iu - solution - excipient ingredients: water for injections; mannitol; sodium acetate; albumin; calcium chloride dihydrate; tributyl phosphate; octoxinol 9 - as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. as suture support for haemostasis in large vessel vascular surgery. for suture line sealing in dura mater closure.

Spojené štáty - angličtina - NLM (National Library of Medicine)

ethicon inc - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen human 85 mg in 1 ml - evicel® fibrin sealant (human) is indicated as an adjunct to hemostasis for use in patients undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical. do not use evicel® : - directly into the circulatory system. intravascular application of evicel® may result in life-threatening thromboembolic events [see warnings and precautions, (5.1) and adverse reactions, (6.2)]. - in individuals known to have anaphylactic or severe systemic reaction to human blood products [see adverse reactions (6.2)]. - for brisk arterial bleeding. - for spraying in endoscopic or laparoscopic procedures in those instances where the minimum recommended distance from the applicator tip to the target site cannot be ensured. [see dosage and administration (2.3)]. risk summary there are no data with evicel® use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with evicel® . it is not known whether

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd - human thrombin, quantity: 4000 iu - solution - excipient ingredients: mannitol; calcium chloride dihydrate; water for injections; sodium acetate; albumin; tributyl phosphate; octoxinol 9 - ? as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. ? as suture support for haemostasis in large vessel vascular surgery. ? for suture line sealing in dura mater closure.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd - human thrombin, quantity: 1600 iu - solution - excipient ingredients: water for injections; mannitol; sodium acetate; albumin; calcium chloride dihydrate; tributyl phosphate; octoxinol 9 - ? as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. ? as suture support for haemostasis in large vessel vascular surgery. ? for suture line sealing in dura mater closure.

Spojené štáty - angličtina - NLM (National Library of Medicine)

ethicon inc - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen human 85 mg in 1 ml - evicel® fibrin sealant (human) is indicated as an adjunct to hemostasis for use in patients undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical. do not use evicel®: - directly into the circulatory system. intravascular application of evicel® may result in life-threatening thromboembolic events [see warnings and precautions, (5.1) and adverse reactions, (6.2)]. - in individuals known to have anaphylactic or severe systemic reaction to human blood products [see adverse reactions (6.2)]. - for brisk arterial bleeding. - for spraying in endoscopic or laparoscopic procedures in those instances where the minimum recommended distance from the applicator tip to the target site cannot be ensured. [see dosage and administration (2.3)]. risk summary there are no data with evicel® use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with evicel® . it is not known whether

Malta - angličtina - Medicines Authority

sandoz limited 200 frimley business park, frimley camberley, surrey gu16 7sr, united kingdom - bimatoprost - eye drops, solution - bimatoprost 0.3 mg/ml - ophthalmologicals

Kanada - angličtina - Health Canada

hill dermaceuticals inc - fluocinolone acetonide - solution - 0.01% - fluocinolone acetonide 0.01% - corticosteroids

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - icodextrin, sodium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium (s)-lactate solution - soln for peritoneal dialysis - per cent - isotonic solutions - peritoneal dialytics, isotonic solutions - it is recommended as a once daily replacement for a single glucose exchange as part of a continuous ambulatory peritoneal dialysis (capd) or automated peritoneal dialysis (apd) regimen for the treatment of chronic renal failure, particularly for patients who have lost ultrafiltration on glucose solutions, because it can extend time on capd therapy in such patients.

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - glucose monohydrate; sodium chloride; calcium chloride dihydrate; magnesium chloride hexahydrate; sodium bicarbonate; sodium (s)-lactate solution - solution for peritoneal dialysis - 1.36 percent weight/volume - hypertonic solutions